PeptiDream Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Patrick Crawford Reid

Chief Executive Officer (CEO)

JP¥180.0m

Compensación total

Porcentaje del salario del CEO	50.0%
Permanencia del CEO	15.7yrs
Participación del CEO	3.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

Mar 03

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Patrick Crawford Reid en comparación con los beneficios de PeptiDream?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	JP¥3b
Sep 30 2023	n/a	n/a	JP¥11b
Jun 30 2023	n/a	n/a	JP¥8b
Mar 31 2023	n/a	n/a	JP¥8b
Dec 31 2022	JP¥180m	JP¥90m	JP¥8b

Compensación vs. Mercado: Patrick Crawford($USD1.19M) está por encima de la media de empresas de tamaño similar en el mercado JP ($USD898.42K).

Compensación vs. Ingresos: Datos insuficientes para comparar la remuneración de Patrick Crawford con los resultados de la empresa.

CEO

Patrick Crawford Reid (48 yo)

15.7yrs

Permanencia

JP¥179,999,000

Compensación

Dr. Patrick Crawford Reid, Ph.D. has been President of PeptiDream Inc. since October 10, 2017 and serves as its CEO. Dr. Reid served as Head of R&D and Senior Vice President at PeptiDream Inc. until Octobe...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Patrick Crawford Reid	President	15.7yrs	JP¥180.00m	3.23% ¥ 6.5b
Kiyofumi Kaneshiro	CFO, Executive VP & Director	6.3yrs	JP¥180.00m	sin datos
Keiichi Masuya	COO, Executive VP & Director	9.3yrs	JP¥180.00m	sin datos
Michio Sasaoka	Independent External Director	no data	sin datos	0.15% ¥ 311.8m
Yukinori Hanafusa	Independent External Director	no data	sin datos	sin datos
Toshio Nagae	Independent External Director	no data	sin datos	0.0059% ¥ 11.8m
Junko Utsunomiya	Independent External Director	3.1yrs	sin datos	sin datos

7.8yrs

Permanencia media

52yo

Promedio de edad

Junta con experiencia: La junta directiva de 4587 se considera experimentada (7.6 años de antigüedad promedio).

PeptiDream Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

PeptiDream Inc., Annual General Meeting, Mar 27, 2024

PeptiDream Inc., Annual General Meeting, Mar 29, 2023

Less than half of directors are independent

Less than half of directors are independent

PeptiDream Inc., Annual General Meeting, Mar 24, 2022

Recent updates

Insufficient new directors

PeptiDream Inc.'s (TSE:4587) 25% Jump Shows Its Popularity With Investors

PeptiDream Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates fall by 17%

Full year 2023 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 27, 2024

Now 21% undervalued

Investor sentiment improves as stock rises 16%

PeptiDream Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 8.0% to JP¥2,817

New minor risk - Share price stability

New major risk - Revenue and earnings growth

PeptiDream Inc. to Report Q3, 2023 Results on Nov 09, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Investor sentiment improves as stock rises 21%

PeptiDream Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus EPS estimates increase by 11%

First quarter 2023 earnings: EPS misses analyst expectations

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2023

PeptiDream Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

PeptiDream Inc., Annual General Meeting, Mar 29, 2023

Consensus EPS estimates increase by 25%

PeptiDream Inc. to Report Q4, 2022 Results on Feb 14, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Second quarter 2022 earnings released: JP¥1.75 loss per share (vs JP¥2.59 profit in 2Q 2021)

Price target decreased to JP¥3,300

PeptiDream Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment deteriorated over the past week

Price target decreased to JP¥3,586

First quarter 2022 earnings released: JP¥6.39 loss per share (vs JP¥3.43 profit in 1Q 2021)

PeptiDream Inc. Provides Consolidated Revenue Guidance for the Fiscal Year Ending December 31, 2022

Less than half of directors are independent

PeptiDream Inc. to Report Q1, 2022 Results on May 12, 2022

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues in line with analyst expectations

PeptiDream Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

PeptiDream Inc., Annual General Meeting, Mar 24, 2022

Price target decreased to JP¥4,413

Price target decreased to JP¥5,038

Third quarter 2021 earnings released: EPS JP¥19.97 (vs JP¥29.81 in 3Q 2020)

PeptiDream Inc. (TSE:4587) signed an agreement to acquire Radiopharmaceutical business of FUJIFILM Toyama Chemical Co., Ltd. from Fujifilm Corporation for ¥30.5 billion.

Full year 2020 earnings released: EPS JP¥35.40 (vs JP¥7.80 loss in FY 2019)

Chairman of the Board Kiichi Kubota has left the company

PeptiDream Inc. to Report Q2, 2021 Results on Aug 05, 2021

PeptiDream Inc. Announces Licensing of Automated PDPS Platform to Ono Pharmaceutical Co., Ltd

New 90-day low: JP¥5,070

Full year 2020 earnings released

PeptiDream Inc. Announces the Resignation of Kiichi Kubota from the Board of Directors

New 90-day high: JP¥6,440

New 90-day high: JP¥5,990

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) completed the acquisition of remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) entered into a merger agreement to acquire the remaining 58% stake in Kleo Pharmaceuticals, Inc from PeptiDream Inc. (TSE:4587) and others.

New 90-day high: JP¥5,730

PeptiDream and Takeda Enter into Collaborative Research and Exclusive License Agreement to Develop Peptide Drug Conjugates for Neuromuscular Disease

PeptiDream Announces Strategic Partnership and License Option Agreement with Amolyt Pharma

PeptiDream Inc. to Report Fiscal Year 2020 Results on Feb 10, 2021

New 90-day high: JP¥5,490

PeptiDream Inc., Fujitsu Limited, Mizuho Capital Co., Ltd., Takenaka Corporation and KISHIDA CHEMICAL CO., LTD. Announces Establishment of Joint Venture

PeptiDream Inc. to Report Q3, 2020 Results on Nov 12, 2020

PeptiDream Inc. to Report Q2, 2020 Results on Aug 06, 2020

Análisis de compensación del CEO

CEO